A new generation of obesity drugs could shift the focus from simply losing weight to losing fat while preserving muscle. One experimental treatment, survodutide, has shown promising results in clinical trials, with patients losing substantial body weight alongside significant reductions in visceral and liver fat. Importantly, most of the weight lost appeared to come from fat rather than lean tissue. Preserving muscle is important because it supports metabolism, blood sugar control, strength and long-term weight maintenance. Researchers are also exploring combination therapies that pair appetite-suppressing drugs with treatments designed to protect muscle, potentially making future weight-loss approaches more effective, healthier and sustainable.
Read more at Firstpost